

HIV | SURVEILLANCE DATA TABLES

**Core Indicators for Monitoring the
Ending the HIV Epidemic Initiative:
(*preliminary data*):**

**National HIV Surveillance System Data
Reported Through June 2025**



U.S. DEPARTMENT OF
HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE
CONTROL AND PREVENTION

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for persons with diagnosed HIV reported to CDC through June 2025.

HIV Surveillance Data Tables is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

Suggested citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through June 2025. *HIV Surveillance Data Tables* 2025;6(2). <https://www.cdc.gov/hiv-data/initiatives/>. Published September 2025. Accessed [date].

On the Web: <https://www.cdc.gov/hiv-data/initiatives/>

Confidential information, referrals, and educational material on HIV

CDC-INFO

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

<http://wwwn.cdc.gov/dcs/ContactUs/Form>

Acknowledgments

This issue of *HIV Surveillance Data Tables* was prepared by the HIV Surveillance Branch, Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention.

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

Technical Notes	4
References	6
Tables	
1a HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2024 through June 2025—United States (preliminary)	7
1b HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2024 through June 2025—United States and 6 territories and freely associated states (preliminary)	8
1c HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2024 through June 2025—United States and 6 territories and freely associated states (preliminary)	9
1d HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2024 through June 2025—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	10
2a Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by selected characteristics, January 2024 through March 2025—United States (preliminary)	12
2b Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by area of residence, January 2024 through March 2025—United States and Puerto Rico (preliminary)	14
2c Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by area of residence, January 2024 through March 2025—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	16
3 Ending the HIV Epidemic Phase I jurisdictions	19

Technical Notes

The *Ending the HIV Epidemic in the U.S.* (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% by 2025 and by 90% by 2030. The Centers for Disease Control and Prevention (CDC) routinely releases *HIV Surveillance Data Tables* on the core indicators for EHE to allow for more timely monitoring of progress. The full list of EHE core indicators and their definitions can be found in the Technical Notes of the *Core indicators for monitoring the Ending the HIV Epidemic initiative* report, available at <https://stacks.cdc.gov/view/cdc/156512>.

The tables included in this report provide *preliminary* data on HIV diagnoses for the years 2024 and 2025 and linkage to HIV medical care for the years 2024 and 2025 based on cases reported to CDC as of June 2025. Data for the 2 indicators are provided at the national, state, and county levels (EHE Phase I jurisdictions only). See Tabulation and Presentation of Data for details on how the indicators are calculated. More information on HIV surveillance practices and limitations, demographic information, and geographic designations can be found in the Technical Notes for the National HIV Surveillance System (NHSS), available at <https://www.cdc.gov/hiv-data/nhss/>.

TABULATION AND PRESENTATION OF DATA

HIV Diagnoses

HIV diagnoses are the numbers of persons aged ≥ 13 years with HIV diagnosed during January 2024 through June 2025 (Tables 1a–d). Data presented were reported (after the removal of personally identifiable information) to CDC.

An evaluation of surveillance data (2019–2023 diagnoses) found that, on average, approximately 80% of HIV diagnoses are reported to CDC during the year of diagnosis and approximately 98% of HIV diagnoses are reported to CDC by the end of the following year. Data for the years 2024 and 2025 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on counting HIV diagnoses can be found in the *HIV Surveillance Report, 2023*, available at <https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-and-prevalence-2025.html>.

Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged ≥ 13 years with HIV diagnosed during January 2024 through March 2025 (Tables 2a–c). The numerator is the number of persons aged ≥ 13 years with HIV diagnosed during January 2024 through March 2025 and who had ≥ 1 CD4 T-lymphocyte (CD4) or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥ 13 years with HIV diagnosed during January 2024 through March 2025. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2024 through March 2025 and reported to NHSS through June 2025. Data for the years 2024 and 2025 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

National analyses include data from the United States, including all 50 states and the District of Columbia. While data for Idaho were included in national and regional analyses, they are not presented in jurisdiction-level tables due to the state's lack of mandatory reporting of all CD4 and viral load test results. Conversely, data for Puerto Rico were not included in national and regional analyses but are available in jurisdiction-level tables.

More information on calculating linkage to care can be found in the report *Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 territories and freely associated states, 2023*, available at <https://www.cdc.gov/hiv-data/nhss/national-hiv-prevention-and-care-objectives-2025.html>.

References

1. HHS. What is *Ending the HIV Epidemic in the U.S.*?. <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>. Updated March 2025. Accessed August 20, 2025.

Table 1a. HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2024 through June 2025—United States (*preliminary*)

	No.	No.
	2024	2025 (January–June)
Sex		
Male	30,658	11,893
Female	7,875	2,898
Age at diagnosis (yr)		
13–24	6,812	2,488
25–34	14,064	5,286
35–44	9,072	3,594
45–54	4,716	1,798
55–64	2,846	1,192
≥65	1,023	433
Race/ethnicity		
American Indian/Alaska Native	191	101
Asian	821	320
Black/African American	15,285	5,938
Hispanic/Latino ^a	12,787	4,628
Native Hawaiian/other Pacific Islander	89	29
White	8,280	3,502
Multiracial	1,080	273
Transmission category^b		
Male-to-male sexual contact ^c	25,152	9,809
Injection drug use ^d		
Male	1,342	529
Female	1,103	415
Male-to-male sexual contact ^c and injection drug use ^d	1,249	475
Heterosexual contact ^e		
Male	2,885	1,067
Female	6,720	2,457
Other ^f		
Male	29	14
Female	53	27
Region of residence^g		
Northeast	5,668	1,864
Midwest	5,335	1,991
South	19,867	8,155
West	7,663	2,781
Total	38,533	14,791

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through June 2025. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

^a Hispanic/Latino persons can be of any race.

^b Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's sex. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^c Includes males who have had sexual contact with other males, and males who have had sexual contact with both males and females.

^d Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^e Heterosexual contact with a person known to have, or with a risk factor for, HIV.

^f Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Region of residence defined by the U.S. Census Bureau. For more information, see <https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html>. Data are based on residence at time of HIV diagnosis.

Table 1b. HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2024 through June 2025—United States and 6 territories and freely associated states (preliminary)

	No. 2024	No. 2025 (January–June)
Sex		
Male	30,949	12,002
Female	7,940	2,922
Age at diagnosis (yr)		
13–24	6,858	2,506
25–34	14,191	5,330
35–44	9,148	3,624
45–54	4,770	1,816
55–64	2,876	1,208
≥65	1,046	440
Race/ethnicity		
American Indian/Alaska Native	191	101
Asian	822	320
Black/African American	15,293	5,938
Hispanic/Latino ^a	13,125	4,756
Native Hawaiian/other Pacific Islander	93	29
White	8,285	3,507
Multiracial	1,080	273
Transmission category^b		
Male-to-male sexual contact ^c	25,362	9,890
Injection drug use ^d		
Male	1,356	532
Female	1,106	415
Male-to-male sexual contact ^c and injection drug use ^d	1,258	475
Heterosexual contact ^e		
Male	2,944	1,091
Female	6,780	2,480
Other ^f		
Male	29	14
Female	54	27
Region of residence^g		
Northeast	5,668	1,864
Midwest	5,335	1,991
South	19,867	8,155
West	7,663	2,781
U.S. territories and freely associated states	356	133
Total	38,889	14,924

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through June 2025. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. U.S. territories and freely associated states include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the U.S. Virgin Islands, and the Republic of Palau.

^a Hispanic/Latino persons can be of any race.

^b Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's sex. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^c Includes males who have had sexual contact with other males, and males who have had sexual contact with both males and females.

^d Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^e Heterosexual contact with a person known to have, or with a risk factor for, HIV.

^f Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Region of residence defined by the U.S. Census Bureau. For more information, see <https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html>. Data are based on residence at time of HIV diagnosis.

Table 1c. HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2024 through June 2025—United States and 6 territories and freely associated states (preliminary)

Area of residence	No.	No.
	2024	2025 (January–June)
Alabama	627	205
Alaska	28	10
Arizona	931	367
Arkansas	321	173
California	4,435	1,503
Colorado	481	174
Connecticut	258	76
Delaware	119	50
District of Columbia	190	63
Florida	4,381	1,923
Georgia	2,462	1,001
Hawaii	85	19
Idaho	47	0
Illinois	1,486	437
Indiana	629	242
Iowa	114	59
Kansas	147	60
Kentucky	369	113
Louisiana	853	481
Maine	67	31
Maryland	783	274
Massachusetts	600	81
Michigan	686	310
Minnesota	310	121
Mississippi	481	213
Missouri	569	203
Montana	28	15
Nebraska	136	28
Nevada	605	198
New Hampshire	31	9
New Jersey	1,162	356
New Mexico	147	102
New York	2,485	831
North Carolina	1,357	624
North Dakota	20	9
Ohio	928	378
Oklahoma	325	147
Oregon	215	104
Pennsylvania	955	463
Rhode Island	96	14
South Carolina	733	287
South Dakota	35	9
Tennessee	874	372
Texas	5,044	1,827
Utah	188	83
Vermont	14	3
Virginia	859	359
Washington	458	201
West Virginia	89	43
Wisconsin	275	135
Wyoming	15	5
Subtotal	38,533	14,791
U.S. territories and freely associated states		
American Samoa	1	0
Guam	4	0
Northern Mariana Islands	0	0
Puerto Rico	337	133
Republic of Palau	0	0
U.S. Virgin Islands	14	0
Subtotal	356	133
Total	38,889	14,924

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of HIV diagnosis. Numbers less than 12 should be interpreted with caution. Data are for cases reported to CDC through June 2025. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 1d. HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2024 through June 2025—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)

Area of residence	No.	No.
	2024	2025 (January–June)
Arizona		
Maricopa County	637	259
California		
Alameda County	180	56
Los Angeles County	1,435	500
Orange County	225	103
Riverside County	294	83
Sacramento County	173	33
San Bernardino County	263	54
San Diego County	415	137
San Francisco County	185	84
District of Columbia	190	63
Florida		
Broward County	557	252
Duval County	254	120
Hillsborough County	281	105
Miami-Dade County	1,052	410
Orange County	427	222
Palm Beach County	334	121
Pinellas County	159	64
Georgia		
Cobb County	151	72
DeKalb County	325	130
Fulton County	477	195
Gwinnett County	227	77
Illinois		
Cook County	1,049	289
Indiana		
Marion County	283	92
Louisiana		
East Baton Rouge Parish	121	49
Orleans Parish	132	83
Maryland		
Baltimore City	178	62
Montgomery County	114	36
Prince George's County	236	74
Massachusetts		
Suffolk County	140	20
Michigan		
Wayne County	291	141
Nevada		
Clark County	551	179
New Jersey		
Essex County	283	84
Hudson County	130	30

Table 1d. HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2024 through June 2025—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)

Area of residence	No.	No.
	2024 (<i>cont</i>)	2025 (January–June) (<i>cont</i>)
New York		
Bronx County	409	135
Kings County	542	172
New York County	329	99
Queens County	421	132
North Carolina		
Mecklenburg County	273	124
Ohio		
Cuyahoga County	151	67
Franklin County	183	90
Hamilton County	122	48
Pennsylvania		
Philadelphia County	380	179
Puerto Rico		
San Juan Municipio	96	45
Tennessee		
Shelby County	318	133
Texas		
Bexar County	383	160
Dallas County	913	338
Harris County	1,269	388
Tarrant County	392	135
Travis County	236	95
Washington		
King County	190	88
Total	18,356	6,707

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of HIV diagnosis. Data are for cases reported to CDC through June 2025. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2024 through March 2025—United States (*preliminary*)

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2024				
Sex					
Male	30,658	25,644	83.6	5,014	16.4
Female	7,875	6,441	81.8	1,434	18.2
Age at diagnosis (yr)					
13–24	6,812	5,595	82.1	1,217	17.9
25–34	14,064	11,768	83.7	2,296	16.3
35–44	9,072	7,575	83.5	1,497	16.5
45–54	4,716	3,889	82.5	827	17.5
55–64	2,846	2,395	84.2	451	15.8
≥65	1,023	863	84.4	160	15.6
Race/ethnicity					
American Indian/Alaska Native	191	162	84.8	29	15.2
Asian	821	705	85.9	116	14.1
Black/African American	15,285	12,370	80.9	2,915	19.1
Hispanic/Latino ^a	12,787	10,976	85.8	1,811	14.2
Native Hawaiian/other Pacific Islander	89	72	80.9	17	19.1
White	8,280	6,896	83.3	1,384	16.7
Multiracial	1,080	904	83.7	176	16.3
Transmission category^b					
Male-to-male sexual contact ^c	25,152	21,158	84.1	3,995	15.9
Injection drug use ^d	2,445	1,980	81.0	465	19.0
Male	1,342	1,099	81.9	243	18.1
Female	1,103	881	79.9	222	20.1
Male-to-male sexual contact ^c and injection drug use ^d	1,249	1,018	81.5	232	18.6
Heterosexual contact ^e	9,605	7,862	81.9	1,743	18.1
Male	2,885	2,346	81.3	539	18.7
Female	6,720	5,516	82.1	1,204	17.9
Region of residence^f					
Northeast	5,668	4,931	87.0	737	13.0
Midwest	5,335	4,515	84.6	820	15.4
South	19,867	16,200	81.5	3,667	18.5
West	7,663	6,439	84.0	1,224	16.0
Total^g	38,533	32,085	83.3	6,448	16.7

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2024 through March 2025—United States (preliminary) (cont)

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2025 (January–March)				
Sex					
Male	7,124	6,024	84.6	1,100	15.4
Female	1,790	1,462	81.7	328	18.3
Age at diagnosis (yr)					
13–24	1,528	1,277	83.6	251	16.4
25–34	3,250	2,745	84.5	505	15.5
35–44	2,138	1,797	84.1	341	15.9
45–54	1,052	886	84.2	166	15.8
55–64	704	588	83.5	116	16.5
≥65	242	193	79.8	49	20.2
Race/ethnicity					
American Indian/Alaska Native	63	56	88.9	7	11.1
Asian	195	170	87.2	25	12.8
Black/African American	3,570	2,948	82.6	622	17.4
Hispanic/Latino ^a	2,860	2,470	86.4	390	13.6
Native Hawaiian/other Pacific Islander	16	13	81.3	3	18.8
White	2,028	1,671	82.4	357	17.6
Multiracial	182	158	86.8	24	13.2
Transmission category^b					
Male-to-male sexual contact ^c	5,886	4,999	84.9	887	15.1
Injection drug use ^d	580	477	82.2	103	17.8
Male	320	262	81.9	58	18.1
Female	260	216	83.1	45	17.3
Male-to-male sexual contact ^c and injection drug use ^d	270	226	83.7	44	16.3
Heterosexual contact ^e	2,151	1,763	81.9	389	18.1
Male	642	531	82.7	110	17.1
Female	1,510	1,231	81.5	279	18.5
Region of residence^f					
Northeast	1,238	1,034	83.5	204	16.5
Midwest	1,205	1,047	86.9	158	13.1
South	4,692	3,887	82.8	805	17.2
West	1,779	1,518	85.3	261	14.7
Total^g	8,914	7,486	84.0	1,428	16.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm³ or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to CDC; therefore, data on linkage to HIV medical care are for persons with HIV diagnosed during January 2024 through March 2025 and reported to NHSS through June 2025. Data are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution. Data are based on residence at time of HIV diagnosis. National analyses include data from the United States, including all 50 states and the District of Columbia. Data for Idaho were included in national and regional analyses; however, they are not presented in jurisdiction-level tables due to the state's lack of mandatory reporting of all CD4 and viral load test results. Conversely, data for Puerto Rico were not included in national and regional analyses but are available in jurisdiction-level tables.

^a Hispanic/Latino persons can be of any race.

^b Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's sex. Because data have been imputed or statistically adjusted to account for missing transmission category, manual calculations of data presented by transmission category may be inaccurate or unreliable and are discouraged. Also, data may not be reported for some populations; therefore, values may not sum to column subtotals and total.

^c Includes males who have had sexual contact with other males, and males who have had sexual contact with both males and females.

^d Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^e Heterosexual contact with a person known to have, or with a risk factor for, HIV.

^f Region of residence defined by the U.S. Census Bureau. For more information, see <https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html>. Data are based on residence at time of HIV diagnosis.

^g Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2024 through March 2025—United States and Puerto Rico (preliminary)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2024				
Alabama	627	431	68.7	196	31.3
Alaska	28	23	82.1	5	17.9
Arizona	931	778	83.6	153	16.4
Arkansas	321	258	80.4	63	19.6
California	4,435	3,732	84.1	703	15.9
Colorado	481	370	76.9	111	23.1
Connecticut	258	229	88.8	29	11.2
Delaware	119	100	84.0	19	16.0
District of Columbia	190	157	82.6	33	17.4
Florida	4,381	3,597	82.1	784	17.9
Georgia	2,462	2,001	81.3	461	18.7
Hawaii	85	69	81.2	16	18.8
Illinois	1,486	1,281	86.2	205	13.8
Indiana	629	506	80.4	123	19.6
Iowa	114	101	88.6	13	11.4
Kansas	147	119	81.0	28	19.0
Kentucky	369	293	79.4	76	20.6
Louisiana	853	697	81.7	156	18.3
Maine	67	56	83.6	11	16.4
Maryland	783	689	88.0	94	12.0
Massachusetts	600	534	89.0	66	11.0
Michigan	686	577	84.1	109	15.9
Minnesota	310	276	89.0	34	11.0
Mississippi	481	349	72.6	132	27.4
Missouri	569	457	80.3	112	19.7
Montana	28	27	96.4	1	3.6
Nebraska	136	108	79.4	28	20.6
Nevada	605	547	90.4	58	9.6
New Hampshire	31	22	71.0	9	29.0
New Jersey	1,162	955	82.2	207	17.8
New Mexico	147	117	79.6	30	20.4
New York	2,485	2,196	88.4	289	11.6
North Carolina	1,357	1,109	81.7	248	18.3
North Dakota	20	19	95.0	1	5.0
Ohio	928	800	86.2	128	13.8
Oklahoma	325	254	78.2	71	21.8
Oregon	215	189	87.9	26	12.1
Pennsylvania	955	837	87.6	118	12.4
Puerto Rico	337	253	75.1	84	24.9
Rhode Island	96	88	91.7	8	8.3
South Carolina	733	648	88.4	85	11.6
South Dakota	35	30	85.7	5	14.3
Tennessee	874	660	75.5	214	24.5
Texas	5,044	4,151	82.3	893	17.7
Utah	188	130	69.1	58	30.9
Vermont	14	14	100	0	0.0
Virginia	859	734	85.4	125	14.6
Washington	458	403	88.0	55	12.0
West Virginia	89	72	80.9	17	19.1
Wisconsin	275	241	87.6	34	12.4
Wyoming	15	13	86.7	2	13.3

Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2024 through March 2025—United States and Puerto Rico (preliminary) (cont)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2025 (January–March)				
Alabama	138	101	73.2	37	26.8
Alaska	8	7	87.5	1	12.5
Arizona	262	231	88.2	31	11.8
Arkansas	102	82	80.4	20	19.6
California	977	835	85.5	142	14.5
Colorado	108	70	64.8	38	35.2
Connecticut	52	46	88.5	6	11.5
Delaware	19	18	94.7	1	5.3
District of Columbia	36	31	86.1	5	13.9
Florida	984	833	84.7	151	15.3
Georgia	614	508	82.7	106	17.3
Hawaii	9	7	77.8	2	22.2
Illinois	312	276	88.5	36	11.5
Indiana	135	106	78.5	29	21.5
Iowa	32	31	96.9	1	3.1
Kansas	33	24	72.7	9	27.3
Kentucky	61	52	85.2	9	14.8
Louisiana	261	225	86.2	36	13.8
Maine	23	19	82.6	4	17.4
Maryland	148	133	89.9	15	10.1
Massachusetts	71	67	94.4	4	5.6
Michigan	177	158	89.3	19	10.7
Minnesota	65	59	90.8	6	9.2
Mississippi	118	89	75.4	29	24.6
Missouri	131	111	84.7	20	15.3
Montana	5	5	100	0	0.0
Nebraska	18	17	94.4	1	5.6
Nevada	129	113	87.6	16	12.4
New Hampshire	6	5	83.3	1	16.7
New Jersey	257	208	80.9	49	19.1
New Mexico	59	57	96.6	2	3.4
New York	519	447	86.1	72	13.9
North Carolina	348	299	85.9	49	14.1
North Dakota	6	6	100	0	0.0
Ohio	210	182	86.7	28	13.3
Oklahoma	85	71	83.5	14	16.5
Oregon	56	51	91.1	5	8.9
Pennsylvania	297	230	77.4	67	22.6
Puerto Rico	75	60	80.0	15	20.0
Rhode Island	10	9	90.0	1	10.0
South Carolina	189	137	72.5	52	27.5
South Dakota	9	8	88.9	1	11.1
Tennessee	203	161	79.3	42	20.7
Texas	1,160	962	82.9	198	17.1
Utah	48	38	79.2	10	20.8
Vermont	3	3	100	0	0.0
Virginia	203	165	81.3	38	18.7
Washington	117	103	88.0	14	12.0
West Virginia	23	20	87.0	3	13.0
Wisconsin	77	69	89.6	8	10.4
Wyoming	1	1	100	0	0.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm³ or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to CDC; therefore, data on linkage to HIV medical care are for persons with HIV diagnosed during January 2024 through March 2025 and reported to NHSS through June 2025. Data are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution. Small numbers, and percentages based on these numbers, should be interpreted with caution. Data are based on residence at time of HIV diagnosis. Data for Idaho were included in national and regional analyses; however, they are not presented in jurisdiction-level tables due to the state's lack of mandatory reporting of all CD4 and viral load test results. Conversely, data for Puerto Rico were not included in national and regional analyses but are available in jurisdiction-level tables.

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2024 through March 2025—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2024				
Arizona					
Maricopa County	637	538	84.5	99	15.5
California					
Alameda County	180	167	92.8	13	7.2
Los Angeles County	1,435	1,197	83.4	238	16.6
Orange County	225	202	89.8	23	10.2
Riverside County	294	227	77.2	67	22.8
Sacramento County	173	139	80.3	34	19.7
San Bernardino County	263	194	73.8	69	26.2
San Diego County	415	363	87.5	52	12.5
San Francisco County	185	174	94.1	11	5.9
District of Columbia	190	157	82.6	33	17.4
Florida					
Broward County	557	452	81.1	105	18.9
Duval County	254	200	78.7	54	21.3
Hillsborough County	281	229	81.5	52	18.5
Miami-Dade County	1,052	836	79.5	216	20.5
Orange County	427	361	84.5	66	15.5
Palm Beach County	334	286	85.6	48	14.4
Pinellas County	159	125	78.6	34	21.4
Georgia					
Cobb County	151	130	86.1	21	13.9
DeKalb County	325	278	85.5	47	14.5
Fulton County	477	382	80.1	95	19.9
Gwinnett County	227	197	86.8	30	13.2
Illinois					
Cook County	1,049	914	87.1	135	12.9
Indiana					
Marion County	283	234	82.7	49	17.3
Louisiana					
East Baton Rouge Parish	121	98	81.0	23	19.0
Orleans Parish	132	109	82.6	23	17.4
Maryland					
Baltimore City	178	159	89.3	19	10.7
Montgomery County	114	99	86.8	15	13.2
Prince George's County	236	207	87.7	29	12.3
Massachusetts					
Suffolk County	140	131	93.6	9	6.4
Michigan					
Wayne County	291	241	82.8	50	17.2
Nevada					
Clark County	551	498	90.4	53	9.6
New Jersey					
Essex County	283	221	78.1	62	21.9
Hudson County	130	106	81.5	24	18.5
New York					
Bronx County	409	355	86.8	54	13.2
Kings County	542	455	83.9	87	16.1
New York County	329	295	89.7	34	10.3
Queens County	421	374	88.8	47	11.2

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2024 through March 2025—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2024 (cont)				
North Carolina					
Mecklenburg County	273	237	86.8	36	13.2
Ohio					
Cuyahoga County	151	135	89.4	16	10.6
Franklin County	183	164	89.6	19	10.4
Hamilton County	122	100	82.0	22	18.0
Pennsylvania					
Philadelphia County	380	326	85.8	54	14.2
Puerto Rico					
San Juan Municipio	96	70	72.9	26	27.1
Tennessee					
Shelby County	318	218	68.6	100	31.4
Texas					
Bexar County	383	307	80.2	76	19.8
Dallas County	913	761	83.4	152	16.6
Harris County	1,269	1,034	81.5	235	18.5
Tarrant County	392	332	84.7	60	15.3
Travis County	236	214	90.7	22	9.3
Washington					
King County	190	168	88.4	22	11.6
Total	18,356	15,396	83.9	2,960	16.1
	2025 (January–March)				
Arizona					
Maricopa County	192	167	87.0	25	13.0
California					
Alameda County	43	40	93.0	3	7.0
Los Angeles County	317	259	81.7	58	18.3
Orange County	59	54	91.5	5	8.5
Riverside County	64	55	85.9	9	14.1
Sacramento County	25	24	96.0	1	4.0
San Bernardino County	41	30	73.2	11	26.8
San Diego County	99	89	89.9	10	10.1
San Francisco County	47	45	95.7	2	4.3
District of Columbia	36	31	86.1	5	13.9
Florida					
Broward County	114	99	86.8	15	13.2
Duval County	60	41	68.3	19	31.7
Hillsborough County	56	44	78.6	12	21.4
Miami-Dade County	225	191	84.9	34	15.1
Orange County	127	108	85.0	19	15.0
Palm Beach County	69	61	88.4	8	11.6
Pinellas County	30	26	86.7	4	13.3
Georgia					
Cobb County	44	37	84.1	7	15.9
DeKalb County	84	69	82.1	15	17.9
Fulton County	119	101	84.9	18	15.1
Gwinnett County	49	42	85.7	7	14.3
Illinois					
Cook County	216	199	92.1	17	7.9

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2024 through March 2025—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
2025 (January–March) (<i>cont</i>)					
Indiana					
Marion County	52	45	86.5	7	13.5
Louisiana					
East Baton Rouge Parish	23	17	73.9	6	26.1
Orleans Parish	44	42	95.5	2	4.5
Maryland					
Baltimore City	34	32	94.1	2	5.9
Montgomery County	24	20	83.3	4	16.7
Prince George's County	36	34	94.4	2	5.6
Massachusetts					
Suffolk County	18	16	88.9	2	11.1
Michigan					
Wayne County	75	64	85.3	11	14.7
Nevada					
Clark County	115	102	88.7	13	11.3
New Jersey					
Essex County	57	48	84.2	9	15.8
Hudson County	23	19	82.6	4	17.4
New York					
Bronx County	85	70	82.4	15	17.6
Kings County	110	95	86.4	15	13.6
New York County	70	59	84.3	11	15.7
Queens County	91	79	86.8	12	13.2
North Carolina					
Mecklenburg County	82	74	90.2	8	9.8
Ohio					
Cuyahoga County	36	35	97.2	1	2.8
Franklin County	49	45	91.8	4	8.2
Hamilton County	34	27	79.4	7	20.6
Pennsylvania					
Philadelphia County	112	97	86.6	15	13.4
Puerto Rico					
San Juan Municipio	21	18	85.7	3	14.3
Tennessee					
Shelby County	74	55	74.3	19	25.7
Texas					
Bexar County	102	85	83.3	17	16.7
Dallas County	210	174	82.9	36	17.1
Harris County	285	235	82.5	50	17.5
Tarrant County	81	68	84.0	13	16.0
Travis County	54	47	87.0	7	13.0
Washington					
King County	47	42	89.4	5	10.6
Total	4,160	3,556	85.5	604	14.5

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm³ or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to CDC; therefore, data on linkage to HIV medical care are for persons with HIV diagnosed during January 2024 through March 2025 and reported to NHSS through June 2025. Data are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution. Data are based on residence at time of HIV diagnosis.

Table 3. Ending the HIV Epidemic Phase I jurisdictions

Counties	Territories	States
Arizona	Puerto Rico	Alabama
Maricopa County	San Juan Municipio	Arkansas
California		Kentucky
Alameda County		Mississippi
Los Angeles County		Missouri
Orange County		Oklahoma
Riverside County		South Carolina
Sacramento County		
San Bernardino County		
San Diego County		
San Francisco County		
District of Columbia		
Florida		
Broward County		
Duval County		
Hillsborough County		
Miami-Dade County		
Orange County		
Palm Beach County		
Pinellas County		
Georgia		
Cobb County		
DeKalb County		
Fulton County		
Gwinnett County		
Illinois		
Cook County		
Indiana		
Marion County		
Louisiana		
East Baton Rouge Parish		
Orleans Parish		
Maryland		
Baltimore City		
Montgomery County		
Prince George's County		
Massachusetts		
Suffolk County		
Michigan		
Wayne County		
Nevada		
Clark County		
New Jersey		
Essex County		
Hudson County		
New York		
Bronx County		
Kings County		
New York County		
Queens County		

Table 3. Ending the HIV Epidemic Phase I jurisdictions (cont)

Counties	Territories	States
North Carolina		
Mecklenburg County		
Ohio		
Cuyahoga County		
Franklin County		
Hamilton County		
Pennsylvania^a		
Philadelphia County		
Tennessee		
Shelby County		
Texas		
Bexar County		
Dallas County		
Harris County		
Tarrant County		
Travis County		
Washington		
King County		

Note. For more information on the Ending the HIV Epidemic in the U.S. initiative, see <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>.